Pharma group Hikma looks to take advantage as Novo Nordisk’s Wegovy and Ozempic start to go off patent next year ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Introduction of a direct-to-patient delivery model for its weight-loss drug in the United States could potentially delay its ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support ...

Hikma launched liraglutide, a generic version of an earlier Novo Nordisk weight loss drug, in the US in December. Liraglutide, which Novo sells as Victoza for diabetes and Saxenda for weight loss, has ...

Hikma Pharmaceuticals (HKMPF) is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents ...

The WHO estimates that 422 million people worldwide suffer from diabetes, with the majority residing in low- or middle-income ...

While bypassing insurance and making Wegovy more affordable should boost ... timeline was provided for the injectable version’s launch in India, a company representative confirmed that Novo ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...

Wegovy was launched in June 2021 ... Zepbound had a later start launch in November 2023. Tirzepatide was taken off the drug shortage list in December 2024. Incidentally, shares of Novo Nordisk ...